Uberflip is the world’s #1 Content Experience Platform (CEP). With tools to aggregate all your marketing content, they empower B2B marketing and sales teams to create personalized content experiences to engage accounts, nurture prospects, and convert leads, without the help of IT. It’s their mission to put control back in the hands of marketing teams to deliver high-converting experiences, that put the customer front and center.

C-Suite On Deck

Responsive image

Q&A with Randy Frisch, CMO at Uberflip

MEDIA 7 | September 26, 2019

Randy Frisch, CMO and Co-Founder at Uberflip has led the content experience movement, prompting marketers to think beyond content creation and focus on the experience.  Randy also co-hosts the Conex Show, a weekly podcast featuring top marketers and their strategies and secrets to success. His talks empower marketers with the strategies they need to capture their audiences, prove their worth, and align their vision. MEDIA 7: If I were to say to a bunch of people who know you, ‘Give me three adjectives that best describe you’, what would I hear? RANDY FRISCH: Determined, passionate, caring. M7: From Flipbooks to the world’s first content experience platform in just 6 years. What are some of the top reasons that helped drive Uberflip to where it is now? RF:  We started as a solution that would allow marketers to share content to readers whenever they wanted and on whichever devices. People still want to consume content whenever they want. Think of the way in which we consume video content on Netflix or music content on Spotify. We’ve been successful in large part because we’ve been able to create a product that marketers need, that make it easier for their buyers to become customers. But that hasn’t been enough. The differentiator for us is culture—the values we strive for as an organization (not just the work environment). I’ll share my 3 favourites here: ? H.U.S.T.L.E.: this one stands for Heart, Unique, Skill, Tech, Lean, Entrepreneurial. My co-founder, Yoav Schwartz, and I actually screen new hires for these traits. ? Valuable, Relevant & Consistent: this one comes from the initial definition of Content Marketing (“creating and distributing valuable, relevant and consistent content”) by Robert Rose and Joe Pullizzi at the Content Marketing Institute. It only makes sense that our teams and employees should expect to be valuable,

Read More

Events

Related News

Medical

UNITED HEALTH FOUNDATION PARTNERS WITH HARRIS-STOWE STATE UNIVERSITY TO CREATE NEW BIOINFORMATICS PROGRAM

Harris-Stowe State University, United Health Foundation | November 20, 2021

news image

The United Health Foundation, the philanthropic foundation of UnitedHealth Group (NYSE: UNH), has awarded a $2 million, three-year grant to Harris-Stowe State University to create a bioinformatics program for undergraduate students at the historically Black university located in St. Louis. Bioinformatics is an emerging field that combines science, physics, math and biology to aid in the diagnosis, treatment and discovery of new therapeutic advancements. An example of bioinformatics is the use of...

Read More

Cell and Gene Therapy

NEUEXCELL THERAPEUTICS AND SPARK THERAPEUTICS ANNOUNCE RESEARCH COLLABORATION AGREEMENT TO DEVELOP A NOVEL GENE THERAPY FOR HUNTINGTON'S DISEASE

NeuExcell Therapeutics | September 13, 2021

news image

NeuExcell Therapeutics and Spark Therapeutics, a member of the Roche Group announced a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering from Huntington's Disease (HD). Under the terms of the agreement, Spark Therapeutics will receive access to NeuExcell's proprietary neuro-regenerative gene therapy platform and capabilities. NeuExcell's research team will collaborate closely with Spark Therapeutics to advance the prog...

Read More

Cell and Gene Therapy

MERCK AND ORNA THERAPEUTICS COLLABORATE TO ADVANCE ORNA’S NEXT GENERATION OF RNA TECHNOLOGY

Merck and Orna Therapeutics | August 17, 2022

news image

Merck known as MSD outside the United States and Canada, and Orna Therapeutics, a biotechnology company pioneering a new investigational class of engineered circular RNA therapies, today announced a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck will make an upfront payment to Orna of $150 million, which will be expensed b...

Read More

Cell and Gene Therapy

TEVOGEN BIO™ FURTHER STRENGTHENS IP PORTFOLIO WITH ADDITIONAL PATENT FOR METHOD OF PREPARING ITS INVESTIGATIONAL SARS-COV-2 SPECIFIC T CELL THERAPY

Tevogen Bio | January 13, 2022

news image

Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, announced that the U.S. Patent and Trademark Office has granted a new patent for the method of preparing COVID-19 peptide specific cytotoxic T cells for the treatment of COVID-19 infection. The patent further reinforces the biotech pioneer’s expanding IP portfolio. “Omicron’s extensive mutations and its subsequent abi...

Read More
news image

Medical

UNITED HEALTH FOUNDATION PARTNERS WITH HARRIS-STOWE STATE UNIVERSITY TO CREATE NEW BIOINFORMATICS PROGRAM

Harris-Stowe State University, United Health Foundation | November 20, 2021

The United Health Foundation, the philanthropic foundation of UnitedHealth Group (NYSE: UNH), has awarded a $2 million, three-year grant to Harris-Stowe State University to create a bioinformatics program for undergraduate students at the historically Black university located in St. Louis. Bioinformatics is an emerging field that combines science, physics, math and biology to aid in the diagnosis, treatment and discovery of new therapeutic advancements. An example of bioinformatics is the use of...

Read More
news image

Cell and Gene Therapy

NEUEXCELL THERAPEUTICS AND SPARK THERAPEUTICS ANNOUNCE RESEARCH COLLABORATION AGREEMENT TO DEVELOP A NOVEL GENE THERAPY FOR HUNTINGTON'S DISEASE

NeuExcell Therapeutics | September 13, 2021

NeuExcell Therapeutics and Spark Therapeutics, a member of the Roche Group announced a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering from Huntington's Disease (HD). Under the terms of the agreement, Spark Therapeutics will receive access to NeuExcell's proprietary neuro-regenerative gene therapy platform and capabilities. NeuExcell's research team will collaborate closely with Spark Therapeutics to advance the prog...

Read More
news image

Cell and Gene Therapy

MERCK AND ORNA THERAPEUTICS COLLABORATE TO ADVANCE ORNA’S NEXT GENERATION OF RNA TECHNOLOGY

Merck and Orna Therapeutics | August 17, 2022

Merck known as MSD outside the United States and Canada, and Orna Therapeutics, a biotechnology company pioneering a new investigational class of engineered circular RNA therapies, today announced a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck will make an upfront payment to Orna of $150 million, which will be expensed b...

Read More
news image

Cell and Gene Therapy

TEVOGEN BIO™ FURTHER STRENGTHENS IP PORTFOLIO WITH ADDITIONAL PATENT FOR METHOD OF PREPARING ITS INVESTIGATIONAL SARS-COV-2 SPECIFIC T CELL THERAPY

Tevogen Bio | January 13, 2022

Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, announced that the U.S. Patent and Trademark Office has granted a new patent for the method of preparing COVID-19 peptide specific cytotoxic T cells for the treatment of COVID-19 infection. The patent further reinforces the biotech pioneer’s expanding IP portfolio. “Omicron’s extensive mutations and its subsequent abi...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Q&A with Randy Frisch, CMO at Uberflip

MEDIA 7 | September 26, 2019

Randy Frisch, CMO and Co-Founder at Uberflip has led the content experience movement, prompting marketers to think beyond content creation and focus on the experience.  Randy also co-hosts the Conex Show, a weekly podcast featuring top marketers and their strategies and secrets to success. His talks empower marketers with the strategies they need to capture their audiences, prove their worth, and align their vision. MEDIA 7: If I were to say to a bunch of people who know you, ‘Give me three adjectives that best describe you’, what would I hear? RANDY FRISCH: Determined, passionate, caring. M7: From Flipbooks to the world’s first content experience platform in just 6 years. What are some of the top reasons that helped drive Uberflip to where it is now? RF:  We started as a solution that would allow marketers to share content to readers whenever they wanted and on whichever devices. People still want to consume content whenever they want. Think of the way in which we consume video content on Netflix or music content on Spotify. We’ve been successful in large part because we’ve been able to create a product that marketers need, that make it easier for their buyers to become customers. But that hasn’t been enough. The differentiator for us is culture—the values we strive for as an organization (not just the work environment). I’ll share my 3 favourites here: ? H.U.S.T.L.E.: this one stands for Heart, Unique, Skill, Tech, Lean, Entrepreneurial. My co-founder, Yoav Schwartz, and I actually screen new hires for these traits. ? Valuable, Relevant & Consistent: this one comes from the initial definition of Content Marketing (“creating and distributing valuable, relevant and consistent content”) by Robert Rose and Joe Pullizzi at the Content Marketing Institute. It only makes sense that our teams and employees should expect to be valuable,

Read More